Cover Image
市場調查報告書

臍帶血幹細胞的全球市場(各保存服務、治療方法、用途、地區)- 規模、市場佔有率、趨勢、分析、機會、成長率、相關資訊及預測

Global Stem Cell Umbilical Cord Blood (UCB) Market (Storage Service, Therapeutics, Application, Geography) - Size, Share, Global Trends, Analysis, Opportunities, Growth, Intelligence and Forecast, 2012 - 2020

出版商 Allied Market Research 商品編碼 295083
出版日期 內容資訊 英文 148 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
臍帶血幹細胞的全球市場(各保存服務、治療方法、用途、地區)- 規模、市場佔有率、趨勢、分析、機會、成長率、相關資訊及預測 Global Stem Cell Umbilical Cord Blood (UCB) Market (Storage Service, Therapeutics, Application, Geography) - Size, Share, Global Trends, Analysis, Opportunities, Growth, Intelligence and Forecast, 2012 - 2020
出版日期: 2014年01月21日 內容資訊: 英文 148 Pages
簡介

臍帶血(UCB)幹細胞被看做能與未來各種確定細胞變換的幹細胞,由於副作用很少可靠性、成本效率可出色地治療,該市場正形成全球醫療產業的主流。目前市場規模是65億美元。預計2013-2020年期間,以33.4%的年複合成長率擴大。

本報告以臍帶血幹細胞的全球市場為焦點,提供保存服務、治療方法、用途,以及北美、歐洲、亞太地區、其他地區的趨勢詳細內容分析、檢驗、市場轉變及發展性分析、預測的最新資訊,及活躍於該市場的主要企業概要與競爭情形彙整,為您概述為以下內容。

第1章 簡介

  • 調查的主要目的
  • 報告主要的優點
  • 從報告取得的主要資訊
  • 報告主要的對象用戶層
  • 調查方法

第2章 摘要整理

  • 臍帶血幹細胞市場 - 各地區(單位:100萬美元)

第3章 臍帶血(UCB)幹細胞的市場概要

  • 市場說明
  • 市場定義和範圍
  • 臍帶血捐血的認識計劃
  • 重要發現
  • 對於末梢血幹細胞,臍帶血幹細胞的優勢點
  • 臍帶血幹細胞的重要優勢點
  • 法規問題、法制、監督當局、報酬問題
  • 幹細胞療法和臍帶血銀行的倫理問題
  • 臍帶血幹細胞的收集方法
  • 臍帶血幹細胞的保存和收集的外部委託
  • 重要專利和新專利分析
  • 臍帶血幹細胞市場上臨床實驗
  • 臍帶血幹細胞市場價值鏈分析
  • 對於臍帶血幹細胞市場,波特的五力分析
  • 臍帶血幹細胞市場動態

第4章 臍帶血幹細胞市場 - 各保存服務

  • 公營、民營臍帶血銀行的差異
  • 市場推動要素
  • 阻礙市場要素
  • 市場機會
  • 公營臍帶血銀行
  • 民營臍帶血銀行

第5章 臍帶血幹細胞市場 - 各治療法

  • 臍帶血幹細胞治療市場(單位:100萬美元)
  • 市場推動要素
  • 阻礙市場要素
  • 機會
  • 癌症及腫瘤疾病
  • 糖尿病
  • 血液疾病
  • 免疫疾病異常
  • 代謝異常
  • 其他的疾病

第6章 臍帶血幹細胞市場 - 各用途

  • 臍帶血幹細胞用途市場(單位:100萬美元)
  • 市場推動要素
  • 阻礙市場要素
  • 機會
  • 幹細胞移植
  • 移植醫療
  • 再生醫療
  • 其他

第7章 臍帶血幹細胞市場 - 各地區

  • 臍帶血幹細胞市場 - 各地區(單位:100萬美元)
  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第8章 企業簡介

  • Cytori Therapeutics Inc.
  • Advanced Cell Technology, Inc. (USA)
  • California Stem Cell
  • Osiris Therapeutics
  • NeoStem Inc.
  • Geron Corporation
  • Opexa Therapeutics, Inc.
  • Athersys, Inc.
  • Pluristem Therapeutics Inc.
  • Mesoblast Limited

圖表一覽

目錄
Product Code: DI 14114

Umbilical cord blood stem cells are potential stem cells that can convert into any type of -determined cells. Global stem cell market is dominating the healthcare industry with its reliable and cost effective method of treatment with fewer side effects. Current market for cord blood therapeutics accounts for $6.5 billion, which is expected to grow at 33.4% CAGR from 2013-2020. Other segments of this market include - Adult stem cell and embryonic stem cells. Government authorities are supporting the research and clinical trials of cord blood stem cell, which is currently increasing the interest of healthcare companies to invest in research and commercialization of cord blood stem cell therapies. Athersys, California Stem Cell Inc., and Cytori Therapeutics Inc. are engaged in the development of novel stem cell therapies from cord blood. Ethical issues regarding cord blood sample application is creating biasness among donor, which is majorly influencing the market.

Competition is currently intense with companies trying to create brand awareness. This is therefore, compelling the market players to formulate market based strategies. Cord blood stem cell is the only type of stem cell that is stored in controlled condition due to its lower volume higher cell count feature. Storage service market is expected grow at 33.4% CAGR from 2013-2020.

KEY BENEFITS:

  • This report provides market intelligence with respect to therapies, applications and storage services in cord blood stem cell market
  • Detailed analysis of top factors influencing the growth of UCB stem cell market so that companies can take developmental decision
  • Value chain analysis, Porter's five forces, top investment pockets are analysed and presented in detail in the report
  • Intelligence of important regulatory and reimbursement issues is provided according to geographies so that companies can take strategic decisions
  • SWOT analysis and strategic developments included in the report for Key players: Advanced Cell Technology, Inc. (USA), Athersys, California Stem Cell Inc., Cytori Therapeutics Inc., Mesoblast, Opexa Therapeutics Geron Corporation, Neostem Inc.

KEY MARKET SEGMENTS

Global Stem cell UCB market by storage

  • Public cord blood banks
  • Private cord blood banks
  • Public Vs. Private UCB banks

Global Stem cell UCB market by Diseases

  • Cancer/ Oncology diseases
  • Acute Leukemia
  • Chronic Leukemia
  • High Risk Solid Tumors
  • Myelodysplastic Syndrome
  • Blood diseases
  • Aplastic Anemia
  • Beta Thalassemia
  • Sickle Cell disease
  • Immune Disorders
  • Leukocyte Adhesion Deficiency
  • Hystiocytic Disorders
  • Wiskott-Aldrich
  • Metabolic Disorders
  • Krabbe Disease
  • Hurler Syndrome
  • Sanfilippo Syndrome
  • Other diseases
  • Osteopetrosis
  • Hemophagoyticlymphohistiocytosis

Global Stem cell UCB market by Technology

  • Stem Cell Transplant
  • Autologous transplant
  • Allogenic transplant
  • Transplant Medicine
  • Regenerative Medicine
  • Others
  • Cord Blood Banking
  • Blood Transfusion
  • Cell Based Genetics

Global Stem cell UCB market by Geography

  • UCB market in North America
  • UCB market in Europe
  • UCB market in Asia-pacific
  • UCB market in ROW

KEY AUDIENCES:

  • Therapeutics service companies
  • Private and government research institutes
  • Academic Institutes
  • Research based pharmaceutical companies
  • Public and Private cord blood banks

Table of Contents

CHAPTER 1 - INTRODUCTION

  • 1.1. Key objectives
  • 1.2. Key benefits
  • 1.3. Key deliverables
  • 1.4. Key audiences
  • 1.5. Research methodology
    • 1.5.1. Secondary research
    • 1.5.2. Primary research
    • 1.5.3. Analyst tools and models

CHAPTER 2 - EXECUTIVE SUMMARY

  • 2.1. Umbilical cord blood stem cell market by Geography , 2012 - 2020, $million

CHAPTER 3 - STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET OVERVIEW

  • 3.1. Market Description
  • 3.2. Market definition and Scope
  • 3.3. Awareness programs for cord blood donation
  • 3.4. Key findings
    • 3.4.1. Top ten factors impacting UCB stem cell market
      • 3.4.1.1. Minimal invasive techniques of collection and transferring
      • 3.4.1.2. Efficient extraction of cord blood
      • 3.4.1.3. Storage service for maintaining viability
      • 3.4.1.4. Government regulation and intervention
      • 3.4.1.5. Ethical issues in storage and application
      • 3.4.1.6. Cost of treatment
      • 3.4.1.7. Availability of treatment and sample
      • 3.4.1.8. Positive engraftment of tissue
      • 3.4.1.9. Efficient transferring during treatment
      • 3.4.1.10. Reimbursement and insurance issues in storage
    • 3.4.2. Top winning strategies
    • 3.4.3. Top Investment pockets
      • 3.4.3.1. UCB stem cell market - by Application
      • 3.4.3.2. UCB market - by Therapeutics
      • 3.4.3.3. UCB market - by Storage service
  • 3.5. Advantages of umbilical cord blood stem cells over peripheral blood stem cells
  • 3.6. Key advantages of UCB stem cells.
    • 3.6.1. Prompt availability
    • 3.6.2. Ease of collection
    • 3.6.3. More tolerance for graft failure
    • 3.6.4. Reduce risk of Graft vs. host disease (GvHD)
    • 3.6.5. Decreased transmission of viral disease infection
  • 3.7. Regulatory issues, legislations and authorities Reimbursement Issues
    • 3.7.1. Regulatory issues of UCB stem cells storage and application (U.S.)
      • 3.7.1.1. American Academy of Pediatrics (AAP)
      • 3.7.1.2. American society for Blood and Marrow Transplantation (ASBMT)
    • 3.7.2. Regulatory issues concenringUCB stem cells storage and application in European countries
    • 3.7.3. Reimbursement issues
  • 3.8. Ethical issues of stem cell therapies and cord blood banking
    • 3.8.1. Ethical issues regarding cord blood banking
    • 3.8.2. Ethical issues in cord blood stem cell therapies
  • 3.9. Umbilical cord blood stem cell collection process
  • 3.10. UCB Stem cells Storage and collection Outsourcing
    • 3.10.1. Stem cell storage and collection outsourcing
      • 3.10.1.1. Criteria for outsourcing of cord blood storage
  • 3.11. Key patents and analysis of Novel Patents
  • 3.12. Clinical trials in UCB stem cell market
    • 3.12.1. Phase 2 Study of stem cell Educator Therapy in Type 1 Diabetes
    • 3.12.2. Safety of Autologous Human Umbilical Cord Blood in the Treatment of Stroke in Children
    • 3.12.3. Longitudinal Study of Immune Mediated Disorders After AllogenicHematopoietic Cell Transplantation (HCT)
    • 3.12.4. Evaluation of Hematopoietic and Immunologic Reconstitution after a Reduced - intensity Conditioning Regimen
    • 3.12.5. Umbilical Cord Blood Transplant for Congenital Pediatrics Disorders
  • 3.13. Value chain analysis of UCB stem cell market
  • 3.14. Porter's five forces analysis for cord blood stem cell market
    • 3.14.1. Higher bargaining power of suppliers for getting competitive advantage
    • 3.14.2. Lower bargaining power of buyers in terms of treatment
    • 3.14.3. Higher degree of competition
    • 3.14.4. Threats of new entrants increases due to novel therapies
    • 3.14.5. Increased threats fromconventional therapies and banking substitutes
  • 3.15. Market Dynamics of UCB stem cell market
    • 3.15.1. Market Drivers
      • 3.15.1.1. Minimal invasive methods
      • 3.15.1.2. Treatment on chronic diseases
      • 3.15.1.3. Cost effective therapy and storage
      • 3.15.1.4. Easy extraction methods
      • 3.15.1.5. Intact genetic structure
    • 3.15.2. Market Restraints
      • 3.15.2.1. Government regulations and intervention
      • 3.15.2.2. Legal and ethical issues during collection
      • 3.15.2.3. Availability of right type of donor
      • 3.15.2.4. Higher cost of therapies
    • 3.15.3. Market Opportunities
      • 3.15.3.1. Advancement in therapeutic application
      • 3.15.3.2. Rising funds for public storage
      • 3.15.3.3. Increase in cost effectiveness to increase APAC market presence

CHAPTER 4 - STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET BY STORAGE SERVICE

  • 4.1. Difference between Public vs. Private UCB banks
    • 4.1.1. Umbilical cord blood stem cell storage service market ,2012 - 2020, $million
  • 4.2. Market Drivers
    • 4.2.1. Lower cost structure
    • 4.2.2. Immediate availability
    • 4.2.3. Government Intervention
    • 4.2.4. Decrease transplant complications
  • 4.3. Market Restraints
    • 4.3.1. Long term storage
    • 4.3.2. Lower volume of blood
    • 4.3.3. Operational Issues
    • 4.3.4. Legal & Ethical Issues
  • 4.4. Market Opportunities
    • 4.4.1. Additional fund collection
    • 4.4.2. Technological adoptions
    • 4.4.3. Insurance as USP
    • 4.4.4. Lowering healthcare costs
  • 4.5. Public cord blood banks
    • 4.5.1. Cost structure of public cord blood banking:
    • 4.5.2. UCB public storage bank service market , 2012 - 2020, $million
  • 4.6. Private cord blood banks
    • 4.6.1. UCB private storage bank service market ,2012 - 2020, $million

CHAPTER 5 - STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET BY THERAPEUTICS

  • 5.1. Umbilical cord blood stem cell therapeutics market , 2012 - 2020, $million
  • 5.2. Market Drivers
    • 5.2.1. Fast recovery
    • 5.2.2. Efficient transferring of stem cells
    • 5.2.3. Minimum invasive technique
    • 5.2.4. Target specific
  • 5.3. Market Restraints
    • 5.3.1. Higher cost of treatment
    • 5.3.2. Scarcity of donor
    • 5.3.3. Rejection in allogenictransplantation
    • 5.3.4. Difficulty in donor matching
  • 5.4. Opportunities
    • 5.4.1. Increasing flexibility
    • 5.4.2. Improved donor policy
    • 5.4.3. Risk management
  • 5.5. Cancer/ Oncology diseases
    • 5.5.1. UCB stem cell cancer therapeutics geography market , 2012 - 2020, $million
    • 5.5.2. UCB stem cell cancer therapeutics market , 2012 - 2020, $million
    • 5.5.3. Acute Leukemia
    • 5.5.4. UCB stem cell Acute leukemia therapeutics market , 2012 - 2020,$million
    • 5.5.5. Chronic Leukemia
    • 5.5.6. GLOBAL UCB stem cell Chronic leukemia therapeutics market , 2012 - 2020, $million
    • 5.5.7. High risk solid tumours
    • 5.5.8. Global UCB stem cell high risk solid tumor therapeutics market , 2012 - 2020, $million
    • 5.5.9. Myelodysplastic syndrome
    • 5.5.10. Global UCB stem cell Myleodysplastic syndrome (MDS) therapeutics market , 2012 - 2020,$million
    • 5.5.11. Others(chronic myelomonocyticleukemia (CMML))
    • 5.5.12. UCB stem cell other disease therapeutics geography market , 2012 - 2020, $million
  • 5.6. Diabetes
    • 5.6.1. Global UCB stem cell diabetes therapeutics market , 2012 - 2020, $million
    • 5.6.2. Global UCB stem cell diabetes therapeutics geography market , 2012 - 2020, $million
    • 5.6.3. Type 1 diabetes
    • 5.6.4. Global UCB stem cell type I diabetes therapeutics geography market, 2012 - 2020, $million
    • 5.6.5. Type 2 diabetes
    • 5.6.6. UCB stem cell Type II diabetes therapeutics geography market , 2012 - 2020, $million
    • 5.6.7. Others(Gestational Diabetes Mellitus(GDM))
    • 5.6.8. UCB stem cell Gestational Diabetes Mellitus(GDM) therapeutics geography market , 2012 - 2020, $million
  • 5.7. Blood diseases
    • 5.7.1. UCB stem cell blood diseases therapeutics market , 2012 - 2020, $million
    • 5.7.2. UCB stem cell blood diseases therapeutics geography market, 2012 - 2020, $million
    • 5.7.3. Aplastic Anemia
    • 5.7.4. Global UCB stem cell Aplastic anemia therapeutics geography market 2012 - 2020, $million
    • 5.7.5. Beta Thalassemia
    • 5.7.6. Global UCB stem cell Thalassemia therapeutics geography market , 2012 - 2020, $million
    • 5.7.7. Sickle Cell disease
    • 5.7.8. Global UCB stem cell Sickle cell disease therapeutics geography market 2012 - 2020, $million
    • 5.7.9. Others (Iron deficiency anemia)
    • 5.7.10. Global UCB stem cell others disease therapeutics geography market , 2012 - 2020, $million
  • 5.8. Immune Disorders
    • 5.8.1. Global UCB stem cell immune disorders therapeutics market , 2012 - 2020, $million
    • 5.8.2. Global UCB stem cell immune disorders therapeutics geography market , 2012 - 2020, $million
    • 5.8.3. Leukocyte Adhesion Deficiency
    • 5.8.4. Global UCB stem cell Leukocyte Adhesion deficiency therapeutics geography market , 2012 - 2020, $million
    • 5.8.5. Hystiocytic disorders
    • 5.8.6. Global UCB stem cell Hystiocytic disorders therapeutics geography market 2012 - 2020, $million
    • 5.8.7. Wiskott - Aldrich
    • 5.8.8. Global UCB stem cell Wiskott - Aldrich therapeutics geography market 2012 - 2020, $million
    • 5.8.9. Others(Inflammatory Bowel Disease (IBD) and Multiple Sclerosis(MS))
    • 5.8.10. Global UCB stem cell others disease therapeutics geography market , 2012 - 2020, $million
  • 5.9. Metabolic Disorders
    • 5.9.1. Global UCB stem cell metabolic disorders therapeutics market , 2012 - 2020, $million
    • 5.9.2. Global UCB stem cell metabolic disorders therapeutics geography market , 2012 - 2020, $million
    • 5.9.3. Krabbe Disease
    • 5.9.4. Global UCB stem cell Krabbe disease therapeutics geography market , 2012 - 2020, $million
    • 5.9.5. Hurler Syndrome
    • 5.9.6. Global UCB stem cell Hurler syndrome therapeutics geography market , 2012 - 2020, $million
    • 5.9.7. Sanfilippo Syndrome
    • 5.9.8. Global UCB stem cell Sanfilippo Syndrome therapeutics geography market , 2012 - 2020, $million
    • 5.9.9. Others (Fabry disease)
    • 5.9.10. Global UCB stem cell Fabry disease therapeutics geography market , 2012 - 2020, $million
  • 5.10. Other diseases
    • 5.10.1. Global UCB stem cell other disease therapeutics market 2012 - 2020, $million
    • 5.10.2. Osteopetrosis
    • 5.10.3. Global UCB stem cell Osteopetrosis disease therapeutics geography market, 2012 - 2020, $million
    • 5.10.4. Hemophagoyticlymphohistiocytosis (HLH)
    • 5.10.5. Global UCB stem cell Hemophagoytic lymphohistiocytosis therapeutics geography market , 2012 - 2020, $million

CHAPTER 6 - STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET BY APPLICATION

  • 6.1. Umbilical cord blood stem cell application market , 2012 - 2020, $million
  • 6.2. Drivers of UCB stem cell application market
    • 6.2.1. Auto - repair process
    • 6.2.2. Pre - surgery management
    • 6.2.3. Disease information
    • 6.2.4. Positive engraftment
  • 6.3. Restraints of UCB stem cell application market
    • 6.3.1. Higher cost of treatment
    • 6.3.2. Genetic variation
    • 6.3.3. Donor Matching
    • 6.3.4. Ethical problem
  • 6.4. Opportunity of UCB stem cell application market
    • 6.4.1. Cost effective regenerative medicines
    • 6.4.2. Wound management therapies
    • 6.4.3. Growing research institute
  • 6.5. Stem Cell Transplant
    • 6.5.1. Global UCB stem cell transplant application market , 2012 - 2020, $million
    • 6.5.2. Autologous transplant
    • 6.5.3. Global UCB stem cell autologous transplant applicationgeogrpahy market 2012 - 2020, $million
    • 6.5.4. Allogenictransplant
    • 6.5.5. Global UCB stem cell allogenic transplant application geography market , 2012 - 2020, $million
  • 6.6. Transplant Medicine
    • 6.6.1. Global UCB stem cell transplant medicine application geography market , 2012 - 2020, $million
  • 6.7. Regenerative Medicine
    • 6.7.1. Global UCB stem cell regenerative medicine application geography market , 2012 - 2020, $million
  • 6.8. Others
    • 6.8.1. Global UCB stem cell other diseases application market , 2012 - 2020, $million
    • 6.8.2. Blood Transfusion
    • 6.8.3. Global UCB stem cell blood tranfusion application geography market 2012 - 2020, $million
    • 6.8.4. Cell Based Genetics
    • 6.8.5. Global UCB stem cell based genetics application geography market , 2012 - 2020, $million

CHAPTER 7 - STEM CELL UMBILICAL CORD BLOOD (UCB) MARKET BY GEOGRAPHY

  • 7.1. Umbilical cord blood stem cell market by geography , 2012 - 2020, $million
  • 7.2. UCB stem cell market in North America
  • 7.3. UCB stem cell market in Europe
  • 7.4. UCB stem cell market in Asia - Pacific
  • 7.5. UCB market in ROW

CHAPTER 8 - COMPANY PROFILES

  • 8.1. Cytori Therapeutics Inc.
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Key Financials of Cytori Therapeutics Inc.
    • 8.1.4. Key Strategies of Cytori Therapeutics Inc.
      • 8.1.4.1. Primary Strategies: Approval
      • 8.1.4.2. Secondary Strategies: Product Launch and Clinical trials
    • 8.1.5. SWOT AnalysisofCytori Therapeutics Inc.
  • 8.2. Advanced Cell Technology, Inc. (USA)
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Key Financials Advanced Cell Technology, Inc. (USA)
    • 8.2.4. Key Strategies Advanced Cell Technology, Inc. (USA)
      • 8.2.4.1. Primary Strategies: Approval
      • 8.2.4.2. Secondary strategies: Study Report
    • 8.2.5. SWOT Analysis Advanced Cell Technology, Inc. (USA)
  • 8.3. California Stem Cell
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot:
    • 8.3.3. Key Strategies California Stem Cell
      • 8.3.3.1. Primary Strategies: Approval
      • 8.3.3.2. Secondary Strategies: Acquisition and clinical trials
    • 8.3.4. SWOT Analysis of California Stem Cell
  • 8.4. Osiris Therapeutics
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot:
    • 8.4.3. Key Financials Osiris Therapeutics
    • 8.4.4. Key Strategies Osiris Therapeutics
      • 8.4.4.1. Primary Strategies: Approval
      • 8.4.4.2. Secondary strategies: Clinical Trials
    • 8.4.5. SWOT analysis of Osiris therapeutics
  • 8.5. NeoStem Inc.
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot:
    • 8.5.3. Key Financials NeoStem Inc.
    • 8.5.4. Key Strategies NeoStem Inc.
      • 8.5.4.1. Primary Strategies: Clinical Trials
      • 8.5.4.2. Secondary Strategies: Collaboration
    • 8.5.5. SWOT AnalysisofNeoStem Inc.
  • 8.6. Geron Corporation
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot:
    • 8.6.3. Key Financials Geron Corporation
    • 8.6.4. Key Strategies Geron Corporation
      • 8.6.4.1. Primary Strategies: Clinical Trials and Investment
      • 8.6.4.2. Secondary Strategies: Collaboration
    • 8.6.5. SWOT Analysis of Geron Corporation
  • 8.7. Opexa Therapeutics, Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot:
    • 8.7.3. Key Strategies Opexa Therapeutics, Inc.
      • 8.7.3.1. Primary Strategies: Approval
      • 8.7.3.2. Secondary Strategies: Agreement
    • 8.7.4. SWOT Analysis of Opexa Therapeutics, Inc.
  • 8.8. Athersys, Inc.
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot:
    • 8.8.3. Key Financials of Athersys, Inc.
    • 8.8.4. Key Strategies Athersys, Inc.
      • 8.8.4.1. Primary Strategies: Clinical Trials
      • 8.8.4.2. Secondary Strategies: Collaboration
    • 8.8.5. SWOT Analysis Athersys, Inc.
  • 8.9. Pluristem Therapeutics Inc.
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot:
    • 8.9.3. Key FinancialsPluristem Therapeutics Inc.
    • 8.9.4. Key Strategies Pluristem Therapeutics Inc.
      • 8.9.4.1. Primary Strategies: Approval& Clearance
      • 8.9.4.2. Secondary Strategies: Product Launch
    • 8.9.5. SWOT Analysis of Pluristem Therapeutics Inc.
  • 8.10. Mesoblast Limited
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot:
    • 8.10.3. Key Financials of Mesoblast Limited
    • 8.10.4. Key Strategies of Mesoblast Limited
      • 8.10.4.1. Primary Strategies: Acquisition
      • 8.10.4.2. Secondary Strategies: Approval
    • 8.10.5. SWOT Analysis ofMesoblast Limited

List of Tables

  • TABLE 1: UMBILICAL CORD BLOOD STEM CELL MARKET BY GEOGRAPHY , 2012-2020, $MILLION
  • TABLE 2: DIFFERENCE BETWEEN PERIPHERAL BLOOD AND CORD BLOOD
  • TABLE 3: CLINICAL TRIALS PHASE 2 STUDY OF STEM CELL EDUCATOR THERAPY IN TYPE 1 DIABETES
  • TABLE 4: UMBILICAL CORD BLOOD STEM CELL STORAGE SERVICE MARKET ,2012-2020, $MILLION
  • TABLE 5: PRICING STRUCTURE OF XYTEXCRYO INTERNATIONAL CORD BLOOD BANK
  • TABLE 6: PRICING STRUCTURE OF PARENT'S GUIDE TO CORD BLOOD FOUNDATION
  • TABLE 7: UCB PUBLIC STORAGE BANK SERVICE MARKET , 2012-2020, $MILLION
  • TABLE 8: PRICING CHART FOR DIFFERENT PRIVATE CORD BLOOD BANKS
  • TABLE 9: UCB PRIVATE STORAGE BANK SERVICE MARKET ,2012-2020, $MILLION
  • TABLE 10: NUMBER OF TRANSPLANT BY NEW YORK BLOOD CENTER (2009)
  • TABLE 11: EMERGING THERAPIES FROM CORD BLOOD STEM IN CHILDREN (2012)
  • TABLE 12: UMBILICAL CORD BLOOD STEM CELL THERAPEUTICS MARKET , 2012-2020, $MILLION
  • TABLE 13: UCB STEM CELL CANCER THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
  • TABLE 14: UCB STEM CELL CANCER THERAPEUTICS MARKET , 2012-2020, $MILLION
  • TABLE 15: UCB STEM CELL ACUTE LEUKEMIA THERAPEUTICS MARKET , 2012-2020,$MILLION
  • TABLE 16: GLOBAL UCB STEM CELL CHRONIC LEUKEMIA THERAPEUTICS MARKET , 2012-2020, $MILLION
  • TABLE 17: GLOBAL UCB STEM CELL HIGH RISK SOLID TUMOR THERAPEUTICS MARKET , 2012-2020, $MILLION
  • TABLE 18: GLOBAL UCB STEM CELL MYLEODYSPLASTIC SYNDROME (MDS) THERAPEUTICS MARKET , 2012-2020,$MILLION
  • TABLE 19: UCB STEM CELL OTHER DISEASE THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
  • TABLE 20: GLOBAL UCB STEM CELL DIABETES THERAPEUTICS MARKET , 2012-2020, $MILLION
  • TABLE 21: GLOBAL UCB STEM CELL DIABETES THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
  • TABLE 22: GLOBAL UCB STEM CELL TYPE I DIABETES THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
  • TABLE 23: UCB STEM CELL TYPE II DIABETES THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
  • TABLE 24: UCB STEM CELL GESTATIONAL DIABETES MELLITUS(GDM) THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
  • TABLE 25: UCB STEM CELL BLOOD DISEASES THERAPEUTICS MARKET , 2012-2020, $MILLION
  • TABLE 26: UCB STEM CELL BLOOD DISEASES THERAPEUTICS GEOGRAPHY MARKET, 2012-2020, $MILLION
  • TABLE 27: GLOBAL UCB STEM CELL APLASTIC ANEMIA THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
  • TABLE 28: GLOBAL UCB STEM CELL THALASSEMIA THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
  • TABLE 29: GLOBAL UCB STEM CELL SICKLE CELL DISEASE THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
  • TABLE 30: GLOBAL UCB STEM CELL OTHERS DIESEA THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
  • TABLE 31: GLOBAL UCB STEM CELL IMMUNE DISORDERS THERAPEUTICS MARKET , 2012-2020, $MILLION
  • TABLE 32: GLOBAL UCB STEM CELL IMMUNE DISORDERS THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
  • TABLE 33: GLOBAL UCB STEM CELL LEUKOCYTE ADHESION DEFICIENCY THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
  • TABLE 34: GLOBAL UCB STEM CELL HYSTIOCYTIC DISORDERS THERAPEUTICS GEOGRAPHY MARKET 2012-2020, $MILLION
  • TABLE 35: GLOBAL UCB STEM CELL WISKOTT-ALDRICH THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
  • TABLE 36: GLOBAL UCB STEM CELL OTHERS.DISEASE THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
  • TABLE 37: GLOBAL UCB STEM CELL METABOLIC DISORDERS THERAPEUTICS MARKET , 2012-2020, $MILLION
  • TABLE 38: GLOBAL UCB STEM CELL METABOLIC DISORDERS THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
  • TABLE 39: GLOBAL UCB STEM CELL KRABBE DISEASE THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
  • TABLE 40: GLOBAL UCB STEM CELL HURLER SYNDROME THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
  • TABLE 41: GLOBAL UCB STEM CELL SANFILIPPO SYNDROME THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
  • TABLE 42: GLOBAL UCB STEM CELL FABRY DISEASE THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
  • TABLE 43: GLOBAL UCB STEM CELL OTHER DISEASE THERAPEUTICS MARKET , 2012-2020, $MILLION
  • TABLE 44: GLOBAL UCB STEM CELL OSTEOPETROSIS DISEASE THERAPEUTICS GEOGRAPHY MARKET, 2012-2020, $MILLION
  • TABLE 45: GLOBAL UCB STEM CELL HEMOPHAGOYTIC LYMPHOHISTIOCYTOSIS THERAPEUTICS GEOGRAPHY MARKET , 2012-2020, $MILLION
  • TABLE 46: UMBILICAL CORD BLOOD STEM CELL APPLICATION MARKET , 2012-2020, $MILLION
  • TABLE 47: GLOBAL UCB STEM CELL TRANSPLANT APPLICATION MARKET , 2012-2020, $MILLION
  • TABLE 48: GLOBAL UCB STEM CELL TRANSPLANT APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLION
  • TABLE 49: GLOBAL UCB STEM CELL AUTOLOGOUS TRANSPLANT APPLICATIONGEOGRPAHY MARKET , 2012-2020, $MILLION
  • TABLE 50: GLOBAL UCB STEM CELL ALLOGENIC TRANSPLANT APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLION
  • TABLE 51: GLOBAL UCB STEM CELL TRANSPLANT MEDICINE APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLION
  • TABLE 52: GLOBAL UCB STEM CELL REGENERATIVE MEDICINE APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLION
  • TABLE 53: GLOBAL UCB STEM CELL OTHER DISEASES APPLICATION MARKET , 2012-2020, $MILLION
  • TABLE 54: GLOBAL UCB STEM CELL BLOOD TRANFUSION APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLION
  • TABLE 55: GLOBAL UCB STEM CELL BASED GENETICS APPLICATION GEOGRAPHY MARKET , 2012-2020, $MILLION
  • TABLE 56: COMPARATIVE ANALYSIS OF MARKET BY GEOGRAPHY
  • TABLE 57: UMBILICAL CORD BLOOD STEM CELL MARKET BY GEOGRAPHY , 2012-2020, $MILLION
  • TABLE 58: CYTORI THERAPEUTICS INC(USA) COMPANY SNAPSHOT
  • TABLE 59: ADVANCED CELL TECHNOLOGIES INC. COMPANY SNAPSHOT
  • TABLE 60: CALIFORNIA STEM CELL INC. COMPANY SNAPSHOT
  • TABLE 61: OSIRIS THERAPEUTICS COMPANY SNAPSHOT
  • TABLE 62: NEOSTEM INC COMPANY SNAPSHOT
  • TABLE 63: GERON CORPORATION COMPANY SNAPSHOT
  • TABLE 64: OPEXA THERAPEUTICS, INC. COMPANY SNAPSHOT
  • TABLE 65: ATHERSYS INC. COMPANY SNAPSHOT
  • TABLE 66: PLURISTEM THERAPEUTICS INC. COMPANY SNAPSHOT
  • TABLE 67: MESOBLAST LIMITED COMPANY SNAPSHOT

List of Figures

  • FIG. 1: SUCCESS RATE FOR UCB STEM CELL TRANSPLANT BASED ON TYPE OF DONORS (2012)
  • FIG. 2: UCB STEM CELL MARKET DEFINITION
  • FIG. 3: PERCENTAGE OF WOMEN TAKING PRESCRIPTION BY PHYSICIANS (2007-2012)
  • FIG. 4: FACTORS IMPACTING ON UCB STEM CELL MARKET
  • FIG. 5: TOP WINING STRATEGIES FOR UCB STEM CELL MARKET FROM 2008-2013
  • FIG. 6: TOP INVESTMENT POCKETS IN UCB CORD BLOOD STEM CELL APPLICATION MARKET (2012-2020)
  • FIG. 7: PERCENTAGE COMPARISON OF CAGR IN THERAPEUTICS MARKET
  • FIG. 8: PERCENTAGE COMPARISON OF CAGR IN STORAGE SERVICE MARKET
  • FIG. 9: CORD BLOOD STEM CELL COLLECTION PROCEDURE
  • FIG. 10: KEY PATENTS FOR UCB STEM CELL FROM 2008-2013
  • FIG. 11: PATENT ANALYSIS FROM 2008-2013
  • FIG. 12: VALUE CHAIN ANALYSIS OF UCB STEM CELL MARKET
  • FIG. 13: PORTER FIVE FORCE MODEL FOR CORD BLOOD STEM CELL MARKET
  • FIG. 14: IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS IN UCB STEM CELL MARKET
  • FIG. 15: CORD BLOOD UNITS ON THE MATCH REGISTRY (2013)
  • FIG. 16: GROWTH IN DISEASE TREATED VS. CLINICAL TRIALS (2008-2012)
  • FIG. 17: AGE GROUP TREATED WITH CORD BLOOD STEM CELL THERAPIES
  • FIG. 18: TOP 10 COUNTRIES IN CANCER POPULATION (PER 100,000 PEOPLE) 2011
  • FIG. 19: CANCER STATISTICS FOR ESTIMATED NEW CASES AND DEATHS IN U.S. FOR 2012
  • FIG. 20: SUBTYPES OF LEUKEMIA CASES IN CHILDREN WORLD-WIDE (2013)
  • FIG. 21: CHRONIC DISEASE BURDEN 2003-2023 ($ BILLIONS)
  • FIG. 22: NUMBER OF AMERICANS WITH CHRONIC DISEASES(FORECASTED)
  • FIG. 23: TREATMENT THERPAIES ON DIABETES, 2011
  • FIG. 24: PREVALENCE OF TYPE-1 DIABETES, BY GEOGRAPHY,IN 2012(IN THOUSANDS)
  • FIG. 25: GLOBAL PREVALENCE OFTYPE-2 DIABETES IN 2000 &ESTIMATED PREVALENCE IN 2030
  • FIG. 26: SINGAPORE CORD BLOOD BANK INVENTORY AND TRANSPLANT (2005-2013)
  • FIG. 27: STEM CELL TRANSPLANT BY CELL SOURCE IN CHILDREN BELOW 18 YEARS
  • FIG. 28: IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS OF UCB STEM CELL APPLICATION MARKET
  • FIG. 29: EMERGING APPLICATION OF CORD BLOOD UNITS IN 2012
  • FIG. 30: TRANSFORMATION OF CORD BLOOD STEM CELL APPLICATION IN REGENERATIVE MEDICINE APPLICATION
  • FIG. 31: GROWTH RATE COMPARISON FOR UCB STEM CELLGEOGRAPHY MARKET (2013-2020)
  • FIG. 32: U.S. FEDRAL SPENDING -FISCAL YEAR 2012
  • FIG. 33: CONCENTRATION OF EUROPEAN STEM CELL THERAPY FIRMS
  • FIG. 34: TOTAL CELL THERAPIES BY TYPES IN EUROPEAN COUNTRIES
  • FIG. 35: DISEASES FACED OR IN FAMILY MEMBERS IN CHINA
  • FIG. 36: SWOT ANALYSIS OF CYTORI THERAPEUTICS INC.
  • FIG. 37: SWOT ANALYSIS OF ADVANCED CELL TECHNOLOGY, INC. (USA)
  • FIG. 38: SWOT ANALYSIS OF CALIFORNIA STEM CELL
  • FIG. 39: SWOT ANALYSIS OSIRIS THERAPEUTICS
  • FIG. 40: SWOT ANALYSISOFNEOSTEM INC.
  • FIG. 41: SWOT ANALYSISOFGERONCORPORATION
  • FIG. 42: SWOT ANALYSIS OF OPEXA THERAPEUTICS, INC
  • FIG. 43: SWOT ANALYSIS OF ATHERSYS, INC.
  • FIG. 44: SWOT ANALYSIS OF PLURISTEM THERAPEUTICS INC.
  • FIG. 45: SWOT ANALYSIS FOR MESOBLAST LIMITED
Back to Top